Fulgent Genetics, Inc. (FLGT) Fair Value 2026

FLGT · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.0 /10

32 fundamental signals · 2 models active

Value Trap Risk

SAFE (9/100)

Quick Summary — As of 2026-08-27, Fulgent Genetics, Inc. (FLGT) trades at $19.95, versus a $12.31 median fair value across its 2 active models — 38.3% below the current price. QOC: 7.0/10. Value Trap Risk: 9/100 (SAFE). 2/13 models active.

Key Facts

Ticker
FLGT
Price
$19.95
Quality Score
7.0/10
Value Trap Risk
9/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Fulgent Genetics, Inc. (FLGT) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Fulgent Genetics, Inc. (FLGT) appears overvalued as of : the median of 2 independent fair value estimates is $12.31, 38.3% below the current price of $19.95. Estimates range from $7.09 to $17.53. FLGT scores 7.0/10 on fundamental quality and 9/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. FLGT’s -38.3% gap is wider than that market norm, and the Diagnostics & Research sector median is -54.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Fulgent Genetics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give FLGT?

2 Intrinsic Value Models vs. Current Price ($19.95)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $7.09 -64.4%
Asset-Based · High Conviction
 $17.53 -12.1%

All Models Active

All 2 models are displayed above.

What Is Fulgent Genetics, Inc. (FLGT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Fulgent Genetics, Inc.'s intrinsic value is estimated at $12.31, suggesting the stock is overvalued at its current price of $19.95. With 2 out of 2 models flagging downside (-38.3% vs price), the market may be pricing in unsustainable growth. Notably, Dynamic NAV sees the most upside at -12.1% (fair value: $17.53), while EPV is the most conservative at -64.4% ($7.09). The spread between these extremes — +52.3% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About FLGT?

2 of 13 models are currently active for FLGT. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for FLGT is $12.31 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does FLGT Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, FLGT ranks #24 by Quality of Company score. CirclFi's QOC score of 7.0/10 evaluates 32 fundamental signals. A score of 7.0 indicates above-average quality.

As a healthcare company, Fulgent Genetics, Inc. operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating FLGT should weigh these sector-specific dynamics alongside our model-derived fair values.

Is FLGT a Value Trap?

CirclFi's Value Trap algorithm assigns FLGT a score of 9/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Fulgent Genetics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Fulgent Genetics, Inc.'s fundamental quality profile registers 7.0/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +52.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every FLGT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across FLGT's 2 active models, average confidence is 61%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Fulgent Genetics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

GHGuardant Health, Inc.QOC 7.0CRLCharles River Laboratories International, Inc.QOC 6.9ADPTAdaptive Biotechnologies CorporationQOC 7.2PRPOPrecipio, Inc.QOC 6.7CDNACareDx, Inc.QOC 7.3XGNExagen Inc.QOC 6.7IMDXInsight Molecular Diagnostics Inc.QOC 6.1ICLRICON Public Limited CompanyQOC 2.8DGXQuest Diagnostics IncorporatedQOC 7.9IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: GH · CRL · ADPT · PRPO · CDNA · XGN · IMDX · ICLR · DGX · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to FLGT?

7 companies across all industries closest to FLGT’s Quality of Company score of 7.0/10.

MEIMethode Electronics, Inc.QOC 7.0KEPKorea Electric Power CorporationQOC 7.0CANCanaan Inc.QOC 7.0OCCOptical Cable CorporationQOC 7.0BSCLBILI Social International, Inc.QOC 7.0YRDYiren Digital Ltd.QOC 7.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MEI · KEP · CAN · OCC · BSCL · YRD · NVDA

What Else Do Investors Ask About Fulgent Genetics, Inc.’s Valuation?

What is Fulgent Genetics, Inc.'s intrinsic value in 2026?

CirclFi puts Fulgent Genetics, Inc. (FLGT)'s intrinsic value at $12.31 — the median of 2 independent model estimates as of 2026-08-27, ranging from $7.09 to $17.53. The Quality of Company score is 7.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is FLGT overvalued or undervalued right now?

At $19.95, 0 of 2 active models suggest FLGT may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $12.31, 38.3% below the current price of $19.95 — a consensus view that FLGT is overvalued. The assessment depends on which methodology best fits Fulgent Genetics, Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 7.0 mean for FLGT?

Fulgent Genetics, Inc.'s QOC of 7.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on FLGT?

CirclFi analyzes FLGT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is FLGT a value trap in 2026?

Fulgent Genetics, Inc.'s Value Trap score is 9/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Fulgent Genetics, Inc. (FLGT) has a median fair value of $12.31 — 38.3% below the current price of $19.95 — as of 2026-08-27.” Source: circlfi.com/stock/FLGT/ · Methodology
Primary sources for this FLGT valuation
  • Financial statements: Fulgent Genetics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001674930) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for FLGT as of ; valuations recomputed .